Low-dose BCG in superficial bladder cancer with strain Connaught Canada--as effective as strain Pasteur Paris?
D
D
Mack
J
J
Frick
D001500:BCG Vaccine / Q000627:therapeutic use*; D002295:Carcinoma, Transitional Cell / Q000628:therapy*; D004306:Dose-Response Relationship, Immunologic; D006801:Humans; D009163:Mycobacterium bovis / Q000145:classification*; D001749:Urinary Bladder Neoplasms / Q000628:therapy*
D001500:BCG Vaccine